The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another ...

Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead ...

Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ: GILD), due to futility. • ...

Gilead Sciences and Arcus Biosciences said they’ve expanded their three-year-old collaboration. An equity stake in Arcus, board seat for Gilead’s commercial chief and a streamlined immuno-oncology ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...

Arcus Biosciences, Inc. (RCUS) shares ended the last trading session 7.8% higher at $24.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Gilead is paying $35 million cash to expand an existing oncology partnership with Arcus Biosciences into inflammatory diseases, giving the biotech the chance to make up to $1 billion in biobucks.

US biotech Arcus Biosciences (NYSE: RCUS) has halted its Phase III STAR-121 study of domvanalimab in first-line ...

The market expects Arcus Biosciences, Inc. (RCUS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known ...